Pathways to prevention: the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program.
作者信息
Nelson Barnaby, Shenton Martha E, Woods Scott W
机构信息
Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
Orygen, Parkville, Victoria, Australia.
出版信息
Schizophrenia (Heidelb). 2025 Apr 15;11(1):62. doi: 10.1038/s41537-025-00605-1.
Abstract
摘要
相似文献
1
Pathways to prevention: the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program.预防途径：加速药物合作组织精神分裂症（AMP® SCZ）项目
Schizophrenia (Heidelb). 2025 Apr 15;11(1):62. doi: 10.1038/s41537-025-00605-1.
2
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.加速药物研发合作组织精神分裂症项目（AMP® SCZ）：精神分裂症前驱症状全球最大前瞻性队列研究的基本原理和研究设计。
Schizophr Bull. 2024 Apr 30;50(3):496-512. doi: 10.1093/schbul/sbae011.
3
Accelerating Medicines Partnership Schizophrenia (AMP SCZ): developing tools to enable early intervention in the psychosis high risk state.加速药物合作精神分裂症项目（AMP SCZ）：开发工具以实现对精神病高危状态的早期干预。
World Psychiatry. 2023 Feb;22(1):42-43. doi: 10.1002/wps.21038.
4
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目的数据分析策略
Schizophrenia (Heidelb). 2025 Apr 3;11(1):53. doi: 10.1038/s41537-025-00561-w.
5
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.加速药物合作组织精神分裂症项目中的认知评估：不同国际样本中的协调重点与策略
Schizophrenia (Heidelb). 2025 Mar 24;11(1):49. doi: 10.1038/s41537-025-00578-1.
6
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目中的样本确定与临床结局指标
Schizophrenia (Heidelb). 2025 Apr 3;11(1):54. doi: 10.1038/s41537-025-00556-7.
7
Accelerating Medicines Partnership in Type 2 Diabetes and Common Metabolic Diseases: Collaborating to Maximize the Value of Genetic and Genomic Data.2型糖尿病和常见代谢疾病加速药物合作组织：携手合作以最大化遗传和基因组数据的价值。
Diabetes. 2025 Jul 1;74(7):1089-1098. doi: 10.2337/db25-0042.
8
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目的磁共振神经成像方案。
Schizophrenia (Heidelb). 2025 Apr 2;11(1):52. doi: 10.1038/s41537-025-00581-6.
9
Kenya Psychosis-Risk Outcomes Study (KePROS): Development of an Accelerated Medicine Partnership Schizophrenia-Aligned Project in Africa.肯尼亚精神病风险结果研究（KePROS）：在非洲开展的一个与精神分裂症相关的加速医学伙伴项目的进展情况
Schizophr Bull Open. 2024 May 4;5(1):sgae009. doi: 10.1093/schizbullopen/sgae009. eCollection 2024 Jan.
10
Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership® Schizophrenia Program.架起科学与希望的桥梁：在加速药物合作组织精神分裂症项目中整合并传达生活经验
Schizophrenia (Heidelb). 2025 Apr 7;11(1):57. doi: 10.1038/s41537-025-00572-7.
引用本文的文献
1
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.加速药物合作精神分裂症项目参与者的基线临床特征
Schizophr Bull Open. 2025 Aug 25;6(1):sgaf012. doi: 10.1093/schizbullopen/sgaf012. eCollection 2025 Jan.
2
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.加速药物合作组织精神分裂症项目的脑电图方案：测量的可靠性与稳定性
Schizophrenia (Heidelb). 2025 Jun 6;11(1):85. doi: 10.1038/s41537-025-00622-0.
本文引用的文献
1
Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership® Schizophrenia Program.架起科学与希望的桥梁：在加速药物合作组织精神分裂症项目中整合并传达生活经验
Schizophrenia (Heidelb). 2025 Apr 7;11(1):57. doi: 10.1038/s41537-025-00572-7.
2
Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program.在复杂的国际多中心研究中实现公平的数据管理：加速药物合作组织精神分裂症项目的数据运营
Schizophrenia (Heidelb). 2025 Apr 3;11(1):55. doi: 10.1038/s41537-025-00560-x.
3
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目中的样本确定与临床结局指标
Schizophrenia (Heidelb). 2025 Apr 3;11(1):54. doi: 10.1038/s41537-025-00556-7.
4
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目的数据分析策略
Schizophrenia (Heidelb). 2025 Apr 3;11(1):53. doi: 10.1038/s41537-025-00561-w.
5
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目的磁共振神经成像方案。
Schizophrenia (Heidelb). 2025 Apr 2;11(1):52. doi: 10.1038/s41537-025-00581-6.
6
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.加速药物合作组织精神分裂症项目中的认知评估：不同国际样本中的协调重点与策略
Schizophrenia (Heidelb). 2025 Mar 24;11(1):49. doi: 10.1038/s41537-025-00578-1.
7
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.加速药物研发合作组织精神分裂症项目（AMP® SCZ）：精神分裂症前驱症状全球最大前瞻性队列研究的基本原理和研究设计。
Schizophr Bull. 2024 Apr 30;50(3):496-512. doi: 10.1093/schbul/sbae011.
8
On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis.首发精神病前前驱期症状患者比例的研究：系统评价和荟萃分析。
Mol Psychiatry. 2024 May;29(5):1361-1381. doi: 10.1038/s41380-024-02415-w. Epub 2024 Feb 2.
9
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS.PSYCHS 的制定：与 SIPS 协调一致的 CAARMS 的积极症状和诊断标准。
Early Interv Psychiatry. 2024 Apr;18(4):255-272. doi: 10.1111/eip.13457. Epub 2023 Aug 28.
10
Accelerating Medicines Partnership Schizophrenia (AMP SCZ): developing tools to enable early intervention in the psychosis high risk state.加速药物合作精神分裂症项目（AMP SCZ）：开发工具以实现对精神病高危状态的早期干预。
World Psychiatry. 2023 Feb;22(1):42-43. doi: 10.1002/wps.21038.
Zotero 插件